Contrasting Aevi Genomic Medicine (GNMX) and Its Rivals
Aevi Genomic Medicine (NASDAQ: GNMX) is one of 95 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Aevi Genomic Medicine to related businesses based on the strength of its valuation, institutional ownership, profitability, risk, dividends, analyst recommendations and earnings.
Earnings and Valuation
This table compares Aevi Genomic Medicine and its rivals revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Aevi Genomic Medicine||N/A||-$37.80 million||-1.58|
|Aevi Genomic Medicine Competitors||$224.58 million||$57.96 million||-1.14|
Aevi Genomic Medicine’s rivals have higher revenue and earnings than Aevi Genomic Medicine. Aevi Genomic Medicine is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Volatility & Risk
Aevi Genomic Medicine has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Aevi Genomic Medicine’s rivals have a beta of 1.13, indicating that their average share price is 13% more volatile than the S&P 500.
This table compares Aevi Genomic Medicine and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aevi Genomic Medicine||N/A||-125.94%||-106.93%|
|Aevi Genomic Medicine Competitors||-910.58%||-183.99%||-27.07%|
Institutional and Insider Ownership
20.8% of Aevi Genomic Medicine shares are owned by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are owned by institutional investors. 15.2% of Aevi Genomic Medicine shares are owned by company insiders. Comparatively, 19.6% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This is a summary of recent ratings and target prices for Aevi Genomic Medicine and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aevi Genomic Medicine||0||1||1||0||2.50|
|Aevi Genomic Medicine Competitors||123||465||1162||11||2.60|
Aevi Genomic Medicine presently has a consensus target price of $4.25, suggesting a potential upside of 163.98%. As a group, “Biotechnology” companies have a potential upside of 56.91%. Given Aevi Genomic Medicine’s higher possible upside, research analysts clearly believe Aevi Genomic Medicine is more favorable than its rivals.
Aevi Genomic Medicine rivals beat Aevi Genomic Medicine on 8 of the 12 factors compared.
Aevi Genomic Medicine Company Profile
Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.
Receive News & Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.